Result Filters
Addressing treatment resistance in the development of cancer immune modulator therapeutics : proceedings of a workshop
- Author(s):
- Nass, Sharyl
- Johnson, Anne Frances
- Zhu, Jennifer
- Balogh, Erin
- National Academies of Sciences Engineering and Medicine Health and Medicine Division Board on Health Sciences Policy Forum on Drug Discovery Development and Translation Board on Health Care Services National Cancer Policy Forum
- Title(s):
- Addressing treatment resistance in the development of cancer immune modulator therapeutics : proceedings of a workshop / Sharyl Nass, Anne Frances Johnson, Jennifer Zhu, Erin Balogh [editors] ; National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation; Board on Health Care Services; National Cancer Policy Forum.
- Country of Publication:
- United States
- Publisher:
- Washington (DC) : National Academies Press (US), 2024.
- Description:
- 1 online resource (1 PDF file (x pages))
-
Language:
- English
- ISBN:
- 9780309716260
0309716268
- Electronic Links:
- https://www.ncbi.nlm.nih.gov/books/NBK601613/
- Summary:
- The use of immune modulator therapeutics, a type of immunotherapy enhancing the body immune system response to cancer, was perceived as the beginning of a new era in cancer care. While still important and frequently used, some of these therapeutics produce uneven response rates, disease resistance, and serious side effects. The National Academies National Cancer Policy Forum, in collaboration with the Forum on Drug Discovery, Development, and Translation, hosted a public workshop to discuss challenges related to immunotherapy treatment resistance, as well as potential policy opportunities to improve the development of immunotherapies for cancer treatment.
- Notes:
- Issued also in print.
This activity was supported by Contract No. 75D30121D11240 (Task Order Nos. 75D30121F00002 and 75D30123F00024) with the Centers for Disease Control and Prevention; Contract No. HHSN263201800029I (Task Order Nos. HHSN26300007, HHSN26300008, 75N98023F00019, and 75N98023F00020) with the National Institutes of Health (National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, and Office of Science Policy); and Grant No. 1R13FD007302-01 with the U.S. Food and Drug Administration. This activity was also supported by the American Association for Cancer Research; American Cancer Society; American College of Radiology; American Society of Clinical Oncology; Amgen Inc.; Association of American Cancer Institutes; Association of American Medical Colleges; Association of Community Cancer Centers; AstraZeneca; Biogen; Bristol Myers Squibb; Burroughs Wellcome Fund; Cancer Support Community; Critical Path Institute; Eli Lilly & Co.; FasterCures, Milken Institute; Flatiron Health; Foundation for the National Institutes of Health; Friends of Cancer Research; Johnson & Johnson; Medable, Inc.; Merck; National Comprehensive Cancer Network; National Patient Advocate Foundation; New England Journal of Medicine; Novartis Oncology; Oncology Nursing Society; Partners in Health; Pfizer Inc; Sanofi; and Society for Immunotherapy of Cancer. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
- NLM ID:
- 9918897701406676 [Electronic Resource]